Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of IW-1973 in Patients With Type 2 Diabetes With Albuminuria Treated With Renin-Angiotensin System Inhibitors
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Sep 2022
Price :
$35
*
At a glance
- Drugs Praliciguat (Primary)
- Indications Diabetic nephropathies
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors Akebia Therapeutics; Cyclerion Therapeutics; Ironwood Pharmaceuticals
- 16 Jun 2020 Results presented at the 80th Annual Scientific Sessions of the American Diabetes Association
- 30 Oct 2019 According to a Cyclerion Therapeutics media release, the company will host a conference call and live audio webcast today o discuss the topline results from this study.
- 30 Oct 2019 According to a Cyclerion Therapeutics media release, full results from this study will be presented at future medical meetings.